Home › FDA Approves Mercks RAGWITEK (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
 

Keywords :   


FDA Approves Mercks RAGWITEK (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults

2014-04-18 00:22:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Robert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: without short treat adults

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05How crops are being disaster-proofed
10.05'I got married on a Thursday and saved 3,000'
10.05Inland Packaging receives Molson Coors Packaging Supplier of the Year
10.05Delays warning as M25 stretch closes for the weekend
10.05AAPI-Owned Three Ships Beauty Raises $2.5 Million
10.05Post Office boss denies covering tracks
10.05Three BASF Women in Manufacturing Honored at the 2024 Women MAKE Awards
10.05BASF Invests in Expansion of Additives Plant in Nanjing
More »